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S
tudies from the laboratory of Roger Unger pre-
sented in the current issue of Diabetes highlight
the potential beneﬁt of reducing glucagon action
by examining the effects of glucagon receptor
knockout (Gcgr
2/2) on the phenotype of type 1 diabetes in
the mouse (1). The aim of the study was to determine if
glucagon action, by itself, causes the lethal consequences
of insulin deﬁciency. Because treatment of Gcgr
2/2 mice
with the b-cell toxin streptozotocin (STZ) previously had
no effect on circulating insulin levels or pancreatic islet
architecture (2), Lee et al. (1) administered a double dose
of STZ to maximize b-cell destruction. Unlike STZ treated
wild-type Gcgr
+/+ mice, which became severely hypergly-
cemic, STZ-treated mice lacking glucagon signaling ap-
peared to be in a normal state of health and were
completely protected from the manifestations of diabetes
(1), as shown previously by the same group in alloxan
treated Gcgr
2/2 mice (3) and by Hancock et al. (4) in STZ-
treated mice lacking glucagon because of a-cell deletion.
Fasting hyperglycemia did not occur in STZ-treated Gcgr
2/2
mice, and astonishingly, the animals demonstrated normal
or even improved glucose disposal in response to a glu-
cose tolerance test, despite the absence of a rise in plasma
insulin. These results led the authors to speculate that in-
sulin action during glucose absorption is largely directed
toward overcoming the hepatic actions of glucagon. They
theorized that insulin would have little or no role in a liver
not exposed to the action of glucagon because it would be
in a permanent glucose storage mode.
Glucagon antagonistic peptides, neutralizing antibodies,
receptor antisense oligonucleotides, and/or receptor non-
peptidyl antagonists have previously been shown to lower
plasma glucose in several rodent models of diabetes (5,6).
Likewise, reversal of diabetes by leptin therapy in the ro-
dent has been attributed to a reduction in plasma glucagon
(3,7), although other actions of leptin could not be ruled
out. Reduction of glucagon in pancreatectomized canines
caused a marked decrease in hepatic glucose production
(8) and suppression of glucagon in diabetic humans im-
proved glucose tolerance (9,10). Thus, there is strong ev-
idence supporting a role for glucagon in contributing to
diabetic hyperglycemia.
Insulin deﬁcient glucagon receptor-null mice are func-
tionally pancreatectomized. Thus, based on the results of
Lee et al. (1), normal glucose metabolism might be
expected in humans with total pancreatectomy, but this is
not the case. Measurement of glucagon is complicated by
nonspeciﬁc cross reacting materials (6), leading to con-
troversy as to whether pancreatectomized patients actu-
ally lack glucagon or not. The consensus, however,
appears to support the concept that glucagon is produced
by the gut in such patients, but at a reduced rate relative to
that produced by the pancreas in individuals with type 1
diabetes (11). This probably explains the less severe,
nonketotic, form of diabetes found in this population (12).
In the pancreatectomized canine, elevated levels of gut
derived glucagon have been shown to contribute to the
severity of the diabetic phenotype (13).
The surprise in the data of Lee et al. (1) comes not from
the improvement in glycemia caused by a lack of glucagon
action, but from the complete normalization of glucose
tolerance that occurred. Transition from the fasted to fed
state involves a reduction in glucose production by the
liver and an increase in glucose disposal by insulin sensi-
tive tissues (skeletal muscle, liver, and adipose tissue).
Studies in the human and canine have indicated that fol-
lowing an oral glucose load of moderate size (;1 g/kg
BW), the liver and skeletal muscle are each responsible for
approximately a third of glucose disposal, with noninsulin
dependant tissues accounting for the remainder (14). In
nondiabetic individuals, the changes in muscle and liver
glucose metabolism are thought to be chieﬂy mediated by
insulin (14). The fact that oral glucose tolerance was
normal in the STZ treated Gcgr
2/2 mice of Lee et al. (1),
despite no rise in insulin, suggests that in a net sense
glucose uptake by liver and muscle was normal. Whether
both tissues took up glucose normally, or one compen-
sated for a defect in the other, is not clear. Nevertheless,
this raises the question as to what is driving glucose dis-
posal if not insulin.
Lee et al. (1) argue that insulin overcomes glucagon’s
inhibitory effects on hepatic glucose uptake (HGU) and
that in the absence of glucagon, the liver will take up
glucose without insulin. Indeed, insulin and glucagon have
opposing effects on many glucoregulatory pathways in the
liver, including transcription of glucokinase and regulation
of glycogen synthesis and breakdown (Fig. 1A). However,
in the normal canine made acutely deﬁcient in insulin and
glucagon using somatostatin and/or pancreatectomy, the
liver did not take up or store glucose when exposed to
a hyperglycemic challenge, despite the lack of glucagon
(15). Likewise, an acute deﬁciency of both insulin and
glucagon in the human (16) or canine (17) led to a tran-
sient fall in glucose production followed by a return to the
basal rate, despite hyperglycemia secondary to decreased
muscle glucose clearance. These data could be interpreted
to suggest that glucagon plays a lesser role in hepatic
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COMMENTARYglucose storage in large animal models and humans than it
does in the rodent. Alternatively, it is possible that the
duration of glucagon lack is important to the phenotype
observed by Lee et al. (1). Leptin (presumably through an
effect on glucagon secretion) normalized glucose within
;10 days of treatment in diabetic mice (3,7). In the canine,
3 days of continuous parenteral nutrition produced an
adaptation in the liver which allowed for sustained net
HGU even in the presence of basal insulin. Further, this
glucose uptake was very sensitive to inhibition by gluca-
gon (18,19).
Although the liver clearly plays an important role in
glucose disposal, skeletal muscle is thought to be at least
as important. In humans, muscle has been shown to ac-
count for 70% of glucose uptake during hyperinsulinemic/
euglycemic clamps (20) and up to 50% after oral glucose
loading (21). Because skeletal muscle is not thought to
express the glucagon receptor, glucagon should not di-
rectly affect muscle glucose uptake (MGU) (Fig. 1A). In-
stead, insulin is the primary regulator, acting to rapidly
increase muscle blood ﬂow, stimulate transmembrane
glucose transport, and activate muscle glycogen synthase
(22). Why then, in the absence of glucagon receptors,
might insulin no longer be required for normal MGU?
Glucagon deﬁciency resulting from genetic deletion of
the a-cell does not appear to affect insulin’s ability to
stimulate MGU because, compared with normal control
animals, there was no difference in insulin stimulated
glucose disposal during a hyperinsulinemic/euglycemic
clamp (4). Muscle selective disruption of the insulin re-
ceptor (23) or GLUT4 (24) results in glucose intolerance in
the presence of glucagon. Therefore, it is surprising that
MGU would appear to have been similar in STZ and non-
STZ–treated Gcgr
2/2 mice, despite arterial insulin levels
that were elevated in one case and very low in the other
(Fig. 2 in ref. 1). One possibility is that blockade of
glucagon action caused the liver to take up more glucose
than normal, thereby overcoming a deﬁcit at muscle. Al-
ternatively, adaptive changes may have occurred in muscle
allowing enhanced noninsulin dependant glucose uptake
to occur. For example, glucose tolerance was not altered
in muscle-speciﬁc insulin receptor knockout mice (25).
Likewise, compensatory insulin-independent muscle glu-
cose transport appeared to occur in whole body GLUT4-
null mice (26). How might a lack of glucagon action have
triggered such a response?
Lack of glucagon may have produced indirect effects on
glucose disposal in muscle through alterations in lipid
homeostasis (Fig. 1C) (2,27). Adipocytes express the glu-
cagon receptor (5) and hypoglucagonemia has been shown
to reduce lipolysis and decrease nonesteriﬁed fatty acid
(NEFA) production by a modest amount (28), although
the extent of glucagon action on adipose tissue in vivo
remains controversial (29). In any event, NEFAs have been
shown to inhibit hepatic and muscle glucose uptake (30).
Indeed, the fasting plasma NEFA levels in the insulin de-
ﬁcient Gcgr
2/2 mice of Lee et al. (1) were almost 70%
lower than those in non-STZ–treated Gcgr
2/2 mice (;0.5
vs. 1.5 nmol/L, respectively; Fig. 3 in ref. 1). Likewise,
circulating NEFA levels were reduced by a third in the
normal canine made acutely deﬁcient in insulin and glu-
cagon using somatostatin and/or pancreatectomy (15).
Therefore, it is plausible that reduced NEFA availability
during fasting may have caused an adaptation allowing for
increased liver and muscle glucose uptake when exposed
to a subsequent glucose load. Thus, by avoiding lipotoxicity
and glucotoxicity, glucagon deﬁciency could indirectly alter
glucose disposal by muscle.
It is important to remember, however, that GLP-1 levels
are dramatically elevated in Gcgr
2/2 mice (2). GLP-1 has
multiple effects on glucose metabolism, most of which are
thought to be secondary to stimulation of insulin secretion,
FIG. 1. A: In the normal state, a meal-related rise in circulating glucose is efﬁciently cleared as the result of reciprocal changes in plasma insulin
and glucagon concentrations. Increased glucose disposal is primarily accounted for by liver and skeletal muscle. Insulin increases disposal by both
organs whereas glucagon opposes insulin at the liver. Insulin also inhibits lipolysis, thus reducing circulating NEFA and further promoting HGU
and MGU. It is unclear what role glucagon may play in regulating lipolysis, although it appears to be minor. B: In type 1 diabetes, insulin is lacking
and the effects of glucagon are unopposed. Glucose disposal is reduced as a result of the inhibitory effects of glucagon on the HGU and lack of
insulin stimulated HGU and MGU. Plasma NEFAs are elevated, perhaps in part as a result of glucagon mediated stimulation of adipose tissue
lipolysis in the absence of insulin. Reduced glucose clearance and increased glucose production leads to glucotoxicity, which in combination with
lipotoxicity, further impairs glucose clearance. C: In STZ-treated Gcgr
2/2 mice, fasting NEFA levels are low, possibly because of the lack of
glucagon action. GLP-1 levels are increased, and together with low NEFA, may create an adaptive state in which glucose disposal occurs normally in
the absence of insulin and glucagon signaling. (A high-quality color representation of this ﬁgure is available in the online issue.)
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emptying. The ﬁrst two mechanisms are not relevant in
STZ treated Gcgr
2/2 mice. Further, because glucose tol-
erance was apparently normal following an IPGTT in the
studies of Lee et al. (1), slowed gastric emptying would not
appear to explain the normal oral glucose tolerance test in
these animals either, although it was a factor in improved
glucose tolerance in non-STZ–treated Gcgr
2/2 mice (2).
GLP-1 has also been shown to directly increase glycogen
synthase a activity in rat hepatocytes (31) and to stimulate
glucose uptake in human myocytes (32). These effects
were blocked by treatment with a phosphatidylinositol 3-
kinase inhibitor, suggesting crosstalk between insulin and
GLP-1 receptor signaling. In vivo, GLP-1 has been shown to
stimulate HGU (33) and MGU (34) independent of an effect
on the b-cell. Thus, it is possible that the high GLP-1 levels
seen in the Gcgr
2/2 mice played a role in normalization of
glucose tolerance (Fig. 1C). This possibility is further sup-
ported by recent studies that demonstrated that Gcgr
antagonist–mediated improvements in glycemic control
were dependent on a functional pancreatic GLP-1 receptor
(35). The role of GLP-1 in improving glycemia in mice
lacking glucagon (4) or treated with leptin (3,7) is unclear
because GLP-1 levels were not measured in those studies.
Taken together, these data raise the possibility that the
presence of increased GLP-1 in the STZ treated Gcgr
2/2
mice might explain at least part of the improved phenotype.
In summary, interfering with glucagon action (by de-
creasing its secretion or inhibiting its action) in the di-
abetic state is beneﬁcial across species. In the rodent,
complete eradication of glucagon action by deletion of the
glucagon receptor is associated with a virtual elimination
of the consequences of STZ induced insulin deﬁciency. At
present it is unclear how deletion of the glucagon receptor
overcomes the need for insulin to stimulate glucose up-
take, presumable by the liver and muscle, but it may relate
to abrogation of the hormone’s action on adipose tissue
and/or the liver. The high level of GLP-1 evident in the STZ
treated Gcgr
2/2 mice may have played a role in the re-
sponse. Clearly, studies need to be carried out in humans
and large animal models in which the effects of complete
chronic or acute glucagon deﬁciency on the diabetic phe-
notype are examined. Further, the sites of glucose disposal
in glucagon deﬁcient STZ treated mice given an oral glu-
cose tolerance test should be identiﬁed, and the ﬂux rates
and signaling pathways involved in glucose disposal
should be determined.
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